This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

M. Keshavan, MD
University of Pittsburgh Medical Center 3811 O'Hara St Pittsburgh, PA 15213

Arch Gen Psychiatry. 1993;50(10):835.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Tandon and Kane¹ provide a thoughtful review of the neuropharmacological profile of the atypical antipsychotic drug, clozapine, in the February 1993 issue of the ARCHIVES. They propose that the in vivo partial agonist effect of clozapine may be relevant for the beneficial effect of clozapine in the treatment of patients with refractory schizophrenia. They derive support for this possibility from the cholinergic-dopaminergic imbalance model of schizophrenia wherein an overactive muscarinic system may diminish the expression of positive psychotic symptoms presumably caused by dopaminergic hyperfunction.² Other pharmacological evidence not reviewed by the authors also supports a role for the muscarinic system in the atypical therapeutic effects of clozapine; muscarinic antagonists attenuate the increase in accumbens and striatum dopamine metabolism produced by clozapine but not by haloperidol.³

Although the cholinergic-dopaminergic model adequately explains the therapeutic effect of clozapine on positive symptoms, it does not explain improvement of negative symptoms. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?